Reminders

Changing Life Sciences Value Chain

Archives for August 2010 « Recent Articles

Photo of Dr. Alan S. LouieOffline

In a recent short report, I highlight the entry of the pharmacy benefits manager (PBM), Medco Health Solutions, into the life science ecosystem with their acquisition of United BioSource Corporation.  Just a few years ago, this acquisition would have passed with little interest, with most people not knowing who either of these companies are and wondering why the announcement was made with a focus on the life sciences.  Times are changing, however, and the relevance of the announcement heralds a ch


Photo of Eric NewmarkOffline

There’s no denying that supply chain security and safety has had a major impact on the pharmaceutical industry over the last decade. Increasing counterfeit activity has placed significant pressure to increase supply chain visibility on an industry that has historically had no true knowledge of the route a product travels from manufacturing to the consumer. Just over the last few months there have been multiple stories around the country of pharmaceutical warehouses broken into and tractor trailers ful


Photo of Dr. Alan S. LouieOffline

As life science companies frantically pursue new drug approvals to replace expiring blockbusters, they are actively tightening their organizations to improve operational efficiency, acquiring promising external drug candidates and companies in hopes of speeding time to market, and pursuing alternative partnerships and collaboration models in hope of gaining competitive advantage and early access to knowledge and/or drug candidates.  With multiple, geographically diverse R&D resources working under


Photo of Eric NewmarkOffline

Over the last several months we have been conducting research in support of our two IT Outsourcing Buyer's Guides (one focused on manufacturing & supply chain, the other on sales & marketing). The first report has now been published and the second is currently being authored and will be published in early September.  As I've previously described, the evaluation criteria revolves around 4 main categories, including industry expertise, delivery expertise, customer references, and industry focus.&


Photo of Dr. Alan S. LouieOffline

We all want free and safe new medical treatments and cures today. Despite this desires and the habit of politicians to pander to their constituencies, the realities of the cost and time required to bring new treatments to market remain unmoved.  It continues to cost a billion dollars and a decade to bring new drugs to market, a reality that is unlikely to change over the foreseeable future.  Technology takes time to deliver on its promise and wishes for faster progress ignore the reality of high s



Viewed 707,843 times